EYEN Stock Overview
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Eyenovia, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.53 |
| 52 Week High | US$5.85 |
| 52 Week Low | US$0.50 |
| Beta | 1.66 |
| 1 Month Change | -54.82% |
| 3 Month Change | -65.53% |
| 1 Year Change | -88.46% |
| 3 Year Change | -89.85% |
| 5 Year Change | -91.70% |
| Change since IPO | -94.65% |
Recent News & Updates
Recent updates
Is Eyenovia (NASDAQ:EYEN) Weighed On By Its Debt Load?
Jan 30
Is Eyenovia (NASDAQ:EYEN) Using Debt In A Risky Way?
Oct 14Is Eyenovia (NASDAQ:EYEN) Using Debt Sensibly?
Jun 27Does Eyenovia (NASDAQ:EYEN) Have A Healthy Balance Sheet?
Oct 25Eyenovia gains as H.C. Wainwright initiates with Buy on pipeline potential
Oct 05Eyenovia names Michael Rowe as new CEO
Jul 27New Forecasts: Here's What One Analyst Thinks The Future Holds For Eyenovia, Inc. (NASDAQ:EYEN)
Apr 03Earnings Beat: Eyenovia, Inc. (NASDAQ:EYEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Mar 31Eyenovia: I Can See You Better - Now
Mar 04Eyenovia: Reassessing After The FDA Moves The Goalposts
Nov 23Eyenovia: FDA Setback Is Big Opportunity For Investors
Nov 08Eyenovia: Can You See Me Now?
Oct 21Is Eyenovia (NASDAQ:EYEN) A Risky Investment?
Sep 16Eyenovia updates on late-stage program for presbyopia therapy
Jun 15Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value Creation
Jun 02Eyenovia announces new $25M credit facility with Silicon Valley Bank
May 10Stuart Grant Just Bought A Sprinkling of Shares In Eyenovia, Inc. (NASDAQ:EYEN)
Mar 09Shareholder Returns
| EYEN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -10.3% | -2.2% | -3.7% |
| 1Y | -88.5% | 11.6% | 20.5% |
Return vs Industry: EYEN underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: EYEN underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| EYEN volatility | |
|---|---|
| EYEN Average Weekly Movement | 17.4% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EYEN's share price has been volatile over the past 3 months.
Volatility Over Time: EYEN's weekly volatility has increased from 13% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 57 | Michael Rowe | www.eyenovia.com |
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company’s product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd.
Eyenovia, Inc. Fundamentals Summary
| EYEN fundamental statistics | |
|---|---|
| Market cap | US$27.05m |
| Earnings (TTM) | -US$27.26m |
| Revenue (TTM) | US$3.79k |
7,144x
P/S Ratio-1.0x
P/E RatioIs EYEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EYEN income statement (TTM) | |
|---|---|
| Revenue | US$3.79k |
| Cost of Revenue | US$3.79k |
| Gross Profit | US$0 |
| Other Expenses | US$27.26m |
| Earnings | -US$27.26m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 0% |
| Net Profit Margin | -719,859.94% |
| Debt/Equity Ratio | 158.8% |
How did EYEN perform over the long term?
See historical performance and comparison